Thymosin Alpha-1 vs TB-500: Immune Support or Tissue Repair-Which Peptide Fits Your Research?

Both peptides start with “thymosin,” but their biology, evidence quality, and legal status are worlds apart. Learn how Thymosin Alpha-1 primes T-cells, why TB-500 targets actin for tissue remodeling, and what today’s 503A review means for ordering either compound in the United States.

Reviewed for general education · Updated July 2026 · 11 min read

Thymosin Alpha-1 is an immune-modulating peptide that boosts T-cell function, while TB-500 is a synthetic fragment of thymosin β-4 studied mainly for speeding soft-tissue repair. Although their names sound similar, they work through entirely different pathways, have very different human evidence records, and sit at different stages of the FDA’s 503A bulk-drug-substance review. Understanding those contrasts helps researchers choose the right tool-or avoid misusing either peptide altogether.

Thymosin Alpha-1 binds toll-like receptor 9 and increases CD4⁺ and CD8⁺ T-cell activation, which may improve antiviral responses according to multiple randomized hepatitis B trials.(pubmed.ncbi.nlm.nih.gov)
TB-500 (a 17-amino-acid fragment of thymosin β-4) weakly binds G-actin, promoting cell migration and angiogenesis in animal tendon and corneal injury models.(jointdrs.org)
Typical research cycles in 2026 use Thymosin Alpha-1 at 1.6 mg subcutaneously twice weekly for 6–12 weeks; TB-500 protocols often start at 5 mg twice weekly for 4 weeks then 5 mg monthly for maintenance.
The FDA Pharmacy Compounding Advisory Committee (PCAC) discussed adding Thymosin Alpha-1 to the 503A Bulks List in October 2024 and TB-500 in July 2026; neither peptide is currently approved.(public-inspection.federalregister.gov)
Most adverse reports involve injection-site irritation; however, immune-suppressed patients should avoid TB-500, and anyone with an autoimmune disorder should consult a physician before Thymosin Alpha-1.

Bottom line: Choose Thymosin Alpha-1 when the goal is immune support, TB-500 when soft-tissue remodeling is the target, and remember that neither peptide is FDA-approved for human use outside research.

Thymosin Alpha-1 and TB-500 Are Distinct Peptides

Thymosin Alpha-1 is a 28-amino-acid peptide derived from the thymus hormone pro-thymosin α that modulates adaptive immunity. It was first isolated in 1977 and later approved in more than 30 countries (not the United States) as an adjuvant therapy for viral hepatitis and certain cancers.

TB-500 is a lab-synthesized 17-amino-acid segment (Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys) that mimics the active region of thymosin β-4. Unlike its parent 43-aa protein, TB-500 is small enough for affordable large-scale synthesis, making it popular in equine medicine and underground sports-medicine circles.

Definition: Immune peptide refers to any short amino-acid chain that modulates innate or adaptive immunity, whereas a healing peptide is one aimed at accelerating tissue repair through angiogenesis, collagen deposition, or cell migration.

For deeper context on tissue-healing peptides, see our guide peptides for healing and the focused TB-500 ACL repair protocol.

Each Peptide Acts on a Different Biological Target

Thymosin Alpha-1 binds intracellular toll-like receptor 9 (TLR-9) and MyD88, up-regulating interleukin-2 and interferon-γ, which expands virus-fighting CD8⁺ cytotoxic T-cells. In hepatitis B trials, the peptide lowered HBV DNA levels and normalized ALT in 25–40 % of participants versus 4–12 % on placebo.(pubmed.ncbi.nlm.nih.gov)

TB-500 binds monomeric (G)-actin, freeing ATP-bound actin needed for cytoskeletal rearrangement and faster cell migration. This actin-sequestering step up-regulates angiogenesis via vascular endothelial growth factor (VEGF) and reduces inflammation by down-modulating NF-κB signaling.

Pathway	Thymosin Alpha-1	TB-500
Primary receptor	TLR-9 / MyD88	G-actin binding
Main downstream effect	↑ CD4⁺ & CD8⁺ T-cells, ↑ IFN-γ	↑ cell migration, ↑ VEGF
Clinical intent	Antiviral immunity, vaccine adjuvant	Tendon, muscle, cornea repair

The Human Evidence Gap Is Much Wider for TB-500

Thymosin Alpha-1 boasts over 50 peer-reviewed human trials, including randomized controlled studies in hepatitis B, sepsis, and, more recently, severe COVID-19. Meta-analyses rate its evidence quality as “moderate” for reducing viral load but “low” for survival benefits in sepsis.

TB-500 has just two small Phase 2 ophthalmology trials in dry-eye patients and no published systemic-use trials. Most efficacy claims come from rodent Achilles-tendon or corneal-wound studies.(pubmed.ncbi.nlm.nih.gov)

Outcome	Thymosin Alpha-1 (human data)	TB-500 (human data)
Randomized trials	≥ 15 RCTs, n > 2,000	2 Phase 2 eye-drop trials, n ≈ 300
Primary endpoints met	HBV DNA ↓ ≥ 2 log in 35 %	Corneal staining ↓ by 33 %
GRADE rating	Moderate	Very low

Typical Research Dosing Cycles Reported in 2026

No human dosing is FDA-approved; the following ranges reflect what academic papers and compounding protocols report, strictly for informational purposes.

Thymosin Alpha-1: 1.6 mg subcutaneously twice weekly (or 0.8 mg three times weekly) for 6–12 weeks. Some investigators extend to 24 weeks in chronic hepatitis protocols.

TB-500: 5 mg subcutaneously twice weekly for 4 weeks (loading), followed by 5 mg once monthly for three months (maintenance). Animal-to-human allometric scaling suggests a safe upper limit near 8 mg per injection for a 200-lb adult, but human safety data are lacking.

Stacking Thymosin Alpha-1 and TB-500: Myths vs Data

Forum anecdotes claim “synergy” when pairing the immune peptide with a healing peptide, especially for stubborn tendon injuries after viral illness. However, no clinical or preclinical study has evaluated this combination. Immunologists point out that actin-binding peptides like TB-500 could hypothetically alter antigen presentation, making additive effects unpredictable.

💡 Key point

If you see sellers marketing a Thymosin Alpha-1 + TB-500 “stack,” ask for published data. None exist as of July 2026.

Where the FDA 503A Review Stands Today

Thymosin Alpha-1: Discussed at the PCAC meeting on October 25 – 26, 2024; the committee deferred a vote, requesting more safety data. Until it appears on the final 503A Bulks List, pharmacies cannot legally compound it for human use.(public-inspection.federalregister.gov)

TB-500: Added to the July 23, 2026 PCAC agenda with wound-healing as the nominated use. A recommendation is expected in Q1 2027. Until then, compounding remains disallowed and import seizures are increasing.(public-inspection.federalregister.gov)

For real-time tracking of peptide deliberations, bookmark our 503A peptide review tracker.

Is either peptide appropriate for your self-experimentation?

Check the column that fits your situation:

✅ Proceed with caution

You have read the full peptide’s animal and human data
You can source third-party sterility and potency testing
You are not pregnant or immunocompromised
You accept that neither peptide is FDA-approved

🏥 Consult a physician first

You have an autoimmune or chronic inflammatory disease
You take immune-suppressing drugs (e.g., prednisone)
You have active cancer or are undergoing chemotherapy
You lack access to sterile injection supplies

Potential Side Effects and Safety Signals

Thymosin Alpha-1: In pooled RCTs, adverse events were mild and included injection-site redness (7 %), transient fever (2 %), and headache (2 %).(pubmed.ncbi.nlm.nih.gov)

TB-500: Human trials using eye drops reported mild eye irritation (9 %) and blurred vision (4 %). Systemic-use anecdotes mention fatigue and mild nausea the day after injections, but no peer-reviewed safety data confirm systemic tolerability.

🚨 When to Contact Your Healthcare Provider

Contact your doctor immediately if you experience any of the following:

High fever (≥ 101 °F) - could signal infection or cytokine storm
Large, painful injection-site swelling - may indicate abscess
New or worsening autoimmune symptoms - joint pain, rashes, flares
Chest pain or shortness of breath - rare allergic or thrombotic reaction
Unexplained bruising or bleeding - possible platelet suppression
Severe eye pain or vision changes after TB-500 eye-drop use
Mental status changes such as confusion or hallucinations
Suicidal thoughts or self-harm urges - call or text 988 (Suicide & Crisis Lifeline, 24/7)

Scientific References

Frequently Asked Questions

Is Thymosin Alpha-1 approved by the FDA?

No. Thymosin Alpha-1 is approved in several Asian and European countries but remains unapproved in the United States. Compounding is prohibited until it appears on the final 503A Bulks List.

Does TB-500 really repair tendons faster?

Animal data show faster collagen deposition and tensile-strength recovery, but no human systemic study has confirmed these effects. Eye-drop trials only assess corneal healing.

Can I take both peptides together for long-COVID?

No data support the combo. Thymosin Alpha-1 has limited evidence in viral infections; TB-500 has none. Combining unapproved peptides could increase unknown risks.

Are these peptides detectable on a drug test?

Standard workplace panels do not screen for peptides, but anti-doping agencies can detect them via LC-MS/MS, and both are banned by WADA.

Why do some sources list TB-500 dosing in “IU”?

International Units are inappropriate for peptides without bioassay standards. Always dose by milligrams and verify concentration with a certificate of analysis.

Can I reconstitute the peptides with bacteriostatic water?

Yes, bacteriostatic water with 0.9 % benzyl alcohol reduces contamination risk. See our guide on bacteriostatic water uses.

How should I store reconstituted Thymosin Alpha-1 or TB-500?

Keep vials refrigerated between 36–46 °F (2–8 °C) and discard after 14 days or if the solution turns cloudy.